HPV vaccines protect against infections that are caused by human papillomaviruses. It is a group of more than 200 related viruses, out of which more than 40 are spread through direct sexual contact. Some HPV types cause genital warts and about a dozen can cause various types of cancer, for instance, cervical, vulvar, penile, anal, vaginal cancer and many more types of cancer. Food and Drug Administration (FDA) has approved mainly 3 types of vaccines that are known to prevent HPV disease namely, Gardasil, Gardasil9, and Cervarix. These vaccines prevent infections of HPV 16 and HPV 18, high risk HPVs that can cause 70% of cervical cancers.
HPV vaccines stimulate the body to produce antibodies that come in contact with HPV, bind to the viruses and prevent it from infecting cells. They are highly effective as they prevent the infections before the exposure to the virus.
The global human papillomavirus vaccine market was valued at USD 2.4 Billion in 2018 and is expected to reach USD 3.9 Billion by 2027. The market is anticipated to record a CAGR of around 5.3% over the forecast period i.e. 2019-2027. The market is segmented by valence, indication & distribution channel. By valence, the market is bi furcated into quadrivalent & non-avalent, bivalent and others out of which, the quadrivalent & bivalent segment is anticipated to have leading shares on account of increasing incidents of cervical cancer and launch of new HPV vaccines. CLICK TO DOWNLOAD SAMPLE REPORT
The market is further segmented by indication into cervical cancer, anal cancer, penile cancer, vulvar cancer, oropharyngeal cancer, genital warts and others out of which, the cervical cancer segment is anticipated to have leading share on account of increasing number of cases of this type of cancer in women and the segment is anticipated to maintain its dominance during the forecast period. Anal cancer is the second largest segment after cervical cancer segment during the forecast period.
On the basis of distribution channel, the market is segmented by physicians, distributors, government entities, public & private alliances and others out of which, public & private alliances segment is anticipated to have leading shares on account of many such alliances such as GAVI, focusing on vaccinating people in developing countries.
There has been high unmet needs in the market and are expected to create vast opportunities for the new entrants and existing players in the market. Various improvements in research and development have led to the development of the HPV vaccines market during the forecast period. As of December 2015, Merck & Co. Inc. stated that U.S. FDA has approved age extension for Gardasil 9, a non avalent HPV vaccine to be used in males of age between 16 to 26 years to prevent the penile and anal cancers and genital warts that are caused by HPV types.
There is an increase in the number of people suffering from various types of cancers worldwide. According to Center for Disease Control and Prevention (CDC), HPV is commonly transmitted infection in U.S. About 90% of anal and cervical cancers, 70% of vulvar and vaginal cancers and 60% of penile cancers are caused by human papillomavirus infection. Additionally, about 14 million people are infected by HPV every year in U.S. This is expected to drive the growth of the HPV vaccine market during the forecast period.
According to the Cancer Council Australia, most of the schools in Australia have participated in the National Papillomavirus Vaccination Program. Among young women and girls in Australia, more than 9 million doses of HPV vaccines have already been given and this initiative led to 90% decrease in genital warts among heterosexual men and women under the age of 21 years and 50% (approx.) decrease in high grade cervical abnormalities in girls under the age of 18 years. This increased participation is expected to drive the growth of the market.
The price of the HPV vaccine is very high and is subject to variations. This factor remains a concern for countries to budget necessary funds for long term. Moreover, people may not be able to afford such high priced vaccines which may lead to severe effects of the diseases caused by HPV. This is expected to hinder the growth of the HPV vaccine market during the forecast period.
Our-in depth analysis of the human papillomavirus vaccine market includes the following segments:
On the basis of regional analysis, the human papillomavirus vaccine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
North America is anticipated to have leading shares on account of increase in recommendations from various associations for immunization practices in U.S. Asia Pacific region is expected to have significant growth during the forecast period. GlaxoSmithKline Plc. has received an approval for Cervarix which is a product of China FDA and is projected to drive the growth of the market in the region. Initiatives taken by Government to reduce infectious diseases caused by HPV is likely to improve the market share of Middle East & Africa region during the forecast period.
The human papillomavirus vaccine market is further classified on the basis of region as follows:
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization